Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Accumulated Expenses (2023 - 2025)

Ascentage Pharma Group International posted quarterly Accumulated Expenses of $381949.0 for Q4 2025, down 81.52% year-on-year from $2.1 million in Q4 2024, and down 81.52% on a QoQ basis from $2.1 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Accumulated Expenses data on file, last reported at $381949.0 in Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 81.52% year-over-year to $381949.0; the trailing twelve-month figure through Dec 2025 stood at $381949.0 (down 81.52% YoY), and the FY2025 full-year result was $387000.0, down 80.97% from the prior year.
  • Accumulated Expenses for Q4 2025 stood at $381949.0, down from $2.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.1 million in Q4 2024 and bottomed at $381949.0 in Q4 2025.
  • The 3-year median for Accumulated Expenses is $568049.4 (2023), against an average of $1.0 million.
  • The widest annual swing landed in 2024, when Accumulated Expenses soared 263.87%; it then tumbled 81.52% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $568049.4 in 2023, then jumped by 263.87% to $2.1 million in 2024, then sank by 81.52% to $381949.0 in 2025.
  • The last three Accumulated Expenses figures came in at $381949.0 (Q4 2025), $2.1 million (Q4 2024), and $568049.4 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 381,948.96
Dec 31, 2024 2.07 Mn
Dec 31, 2023 568,049.44